Navigation Links
New target for anti-flu drug development
Date:9/22/2007

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.

Their findings have been published in the August 15, 2007 issue of the journal Cell Cycle.

The potential drug target is the flu protein M2, long known to be highly conserved between avian and human strains of the virus. Scientists at Cure Lab found that this M2 protein may single-handedly kill human cells.

This effect may constitute a previously unknown mechanism of influenza virus pathogenicity said Dr. Alex Shneider, senior author on the paper and CEO of the company. If so, drugs that are shown to prevent M2-dependent cell killing have the potential to be used for the treatment of flu.

Membranes covering human and avian cells do not allow ions to move in and out of the cell freely, thus maintaining internal homeostasis. M2 protein of flu virus forms ion channels allowing ion trafficking into cells that cells no longer control. Dr. Shneider and his group not only demonstrated that M2 kills mammalian cells, but also showed that ion channeling through M2 pores may be a molecular mechanism of this cell killing process. Dr. Shneider said that Developing drugs which block M2 ion channels could reduce or eliminate M2-induced cell death, and thus may be a new strategy for targeted development of anti-influenza drugs.

In collaboration with Dr. Vladimir L. Gabai from Boston University, and Dr. Shamil R. Sunyaev from Harvard Medical School scientist from Cure Lab, Inc. have developed mutant forms of M2 protein, where the ion channel is blocked. The researchers have shown that these specific mutations they introduced in the protein significantly reduces its ability to kill the cell. From the point of view of the pharmaceutical industry and feasibility studies, introducing mutations into a protein, which mimic an effect of a future drug, is a way to validate the feasibility of a drug target.

Dr. Shneider said that an M2-targeted search for new anti-influenza drugs could lead to a new generation of medicines which will complement those currently used for influenza disease prevention and treatment. Dr. Petr Ilyinskii, a principal scientist at Cure Lab and the first author on the paper also pointed out that This is especially important since an increasing number of influenza strains are becoming resistant to the drugs that are now widely used.


'/>"/>

Contact: Alex Shneider
thoidis@curelab.com
609-841-1201
Cure Lab, Inc.
Source:Eurekalert

Related biology technology :

1. Enhanced Amplification of Long Targets with PfuTurbo DNA Polymerase
2. Microarray Target Purification Kit and the Microarray Target Synthesis Kit (T7)
3. Gene Expression Arrays: Highly Sensitive Detection of Expression Patterns with Improved Tools for Target Amplification
4. Detection of antibody-stained cell surface and intracellular protein targets with the Agilent 2100 bioanalyzer
5. Protect RNA and Improve Target Cell Identification
6. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays
7. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
8. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
9. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
10. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
11. TomoTherapy revises IPO money target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 ASAE is introducing a hybrid membership ... (AMC) the option of joining or renewing through an ... by staff size, every employee in any size association ... reap all available member benefits.   John ... membership options will allow organizations of any size and ...
(Date:2/10/2016)... -- Allergan plc (NYSE: AGN ) a leading global ... Allergan,s CEO and President, will be featured as the ... RBC Capital Markets Healthcare Conference on Tuesday, February 23, ... Palace Hotel in New York, NY ... be accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, has ... More than 1,600 participants have joined the PROMPT study, which seeks to advance ...
Breaking Biology Technology:
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
Breaking Biology News(10 mins):